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Abstract
Cholera, also known as “blue death” is a potentially epidemic and life-threatening secre-
tory diarrhea characterized by numerous voluminous watery stools, often accompanied 
by vomiting and resulting in hypovolemic shock and acidosis. The causative agent of this 
water-borne disease belongs to certain members of the species Vibrio cholerae (V. cholerae) 
which can also cause mild or unapparent infections. V. cholerae is a facultative anaerobic, 
Gram-negative bacilli, which possess the characteristic feature of darting motility under 
wet-mound preparations. Other members of the species may occasionally cause isolated 
outbreaks of milder diarrhea, whereas others—the vast majority—are free-living and not 
associated with disease. The emergence of new, virulent, drug-resistant strains of Vibrio 
is the main cause of protracted outbreaks leading to high fatality rates. The subsequent 
loss of fluid volume causes a drop in blood pressure and circulatory shock. If the patient 
remains untreated, they become progressively weaker, sometimes to the point of death, 
within 12–24 h of the onset of symptoms. The severity and fatality of the disease depend 
on the strain of Vibrio. The cholera toxin-producing (CT-producing) V. cholerae manifests 
the most fatal disease known as cholera gravis. Throughout most of the twentieth cen-
tury, cholera was caused by V. cholerae of the O1 serogroup, and the disease was largely 
confined to Asia and Africa. The emergence of a pandemic in 1992 was caused by an 
unknown serogroup of V. cholerae (O139) wherein the targets were India and Bangladesh. 
The pathogenesis and virulence of the bacteria are due to an enterotoxin it produces—
cholera toxin (CT). The mechanism of action of CT is discussed in this chapter at a later 
stage. Attempts have been made to produce vaccines through a number of trial-and-error 
methods, and still the possibility of an effective vaccine which gives a good prophylactic 
measure is under consideration. The identification of the bacteria as well as toxin detec-
tion is one of the main elements in the clinical microbiology field. The identification and 
confirmation of this epidemic disease commend from the morphological identification of 
Vibrio and end with serotyping and biotyping in addition to toxin detection by various 
means of assays—both in vitro and in vivo. This chapter will cover all of the mentioned 
areas of clinical microbiology with respect to cholera infection in addition to the recent 
outbreaks and epidemics which occurred across the globe.
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1. Introduction
Cholera, a water-borne infectious disease (also known as “blue death”), is characterized by 
life-threatening secretory diarrhea often accompanied by numerous voluminous watery 
stools and vomiting, eventually leading to hypovolemic shock and acidosis. The term “blue 
death” is given to the disease as it changes the skin of the infected individuals to blue dis-
coloration due to severe dehydration [1, 2]. It is caused by certain members of the species V. 
cholerae which can also cause mild or unapparent infections. These bacteria are found in water 
or food contaminated with feces. Countries with poor water and sewage treatment are likely 
to be the victims of cholera. This disease is very unlikely to be spread from person to person. 
The history of cholera began in the nineteenth century where millions of people across the 
continents were vanished due to six subsequent pandemics. South Asia in 1961 witnessed the 
seventh pandemic, Africa in 1971, and the Americas in 1991 [3]. The outcome of humanitar-
ian crisis, like overcrowded camps, and lack of water and sanitation systems are some of 
the factors which increase the risk of cholera transmission. The presumptive confirmation of 
cholera is done on the primary clinical investigation of watery stools and severe dehydration. 
Nowadays the use of rapid identification kits has eased the detection of cholera within a few 
hours of receiving the sample in the laboratory [2, 3]. The failure to produce an effective oral 
vaccine against cholera is the area where the professionals and researchers are worried about. 
The different trials and attempts to produce a vaccine and the vaccines under trial are further 
discussed in the chapter. The clinical microbiology of cholera, its epidemiology and the labo-
ratory investigations are discussed in detail in this chapter.
2. Clinical features
2.1. Symptoms
The symptoms of the cholera disease usually manifest 1–3 days after ingestion of contami-
nated food and/or water. In most cases, the symptoms range from mild to moderate, but in 
20% of cases, severe life-threatening fatal conditions appear. The most severe manifestation of 
the disease, “cholera gravis,” affects only minority of the patients infected with CT-producing 
V. cholerae [1]. It has been estimated that classical strains are more virulent than El Tor strains. 
The incubation period of cholera is dependent on inoculum size and ranges from several 
hours to 5 days [2]. The onset of the clinical manifestation may be sudden profuse watery 
diarrhea followed by anorexia and abdominal discomfort in some cases. Initially the stool will 
be dark brown with solid nature; gradually it turns to inoffensive whitish watery stool giving 
a rice water appearance [1]. This is the characteristic nature of cholera which helps to diagnose 
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from the other gastrointestinal infections. The massive fluid loss via vomiting and excessive 
diarrhea is due to the action of enterotoxins produced by the V. cholerae [3]. Enterotoxins are 
cytotoxic and alter the permeability of the epithelial cells of the intestinal wall by creating 
pores. As a result of osmosis, the water and other fluid substances flow out of the body lead-
ing to massive diarrhea and severe dehydration [4]. Vomiting is also present which develops 
after the onset of diarrhea. In cholera gravis the rate of diarrhea reaches a maximum to 600–
1000 ml/h leading to hypotension, tachycardia and vascular collapse. Due to severe dehydra-
tion, the skin turgor will be poor, giving a dry appearance, with eyes sunken. The patient will 
be restless and thirsty, and the hands will show wrinkles as after a long immersion which is 
often referred to as “washer woman’s hands.” The drastic hypovolemic shock leads to hypo-
kalemia resulting in painful muscle cramps and in severe cases hypokalemic nephropathy 
and focal myocardial necrosis. Body temperature will be quite normal except for 20% of the 
infected individuals which shows a slight temperature rise [4–6].
Lactic acidosis and stool bicarbonate losses associated with dehydration are manifested by 
decrease of blood pH and plasma bicarbonate and an increased serum anion gap (mean of 
20.2 mmol/l in a study). Despite potassium loss, untreated acidosis usually leads to high 
potassium levels in serum. In children, hypoglycemia associated with coma and convulsions 
may occur [4, 6].
2.2. Mechanism of pathogenesis
A better understanding of the source of infection is very much necessary for the management 
and effective prophylaxis of any diseases. In the case of cholera, contaminated water and 
feces of persons infected with V. cholerae are the primary sources of infection. Planktons and 
zooplankton harboring the infectious agent and certain environmental factors such as surface 
change and terrestrial nutrient discharge are also among the factors that indirectly lead to the 
production of more hosts [7].
The mechanism of invasion begins as soon as the bacterium establishes itself in the bowel, 
following the colonization of the epithelial layer of the small intestine by penetrating the 
mucous. The penetration of the mucous is facilitated by mucolytic enzymes which help to 
destroy the mucous integrity, and also the long tail of the invading organism allows it to 
propel itself through the thick mucosal layer. The attachment Vibrio onto the microvilli of the 
small intestine is aided by the so-called pili on the bacterium which is one of the major factors 
which attributes to the darting motility [6, 8]. The production of an endotoxin by the bacteria, 
called CT, is the major key for the virulence mechanism. So it is proved that only toxigenic 
strains of Vibrio, i.e., Vibrio that produces CT, are capable of causing cholera. Studies suggest 
that this CT is encoded by a filamentous bacteriophage which is harbored by pathogenic 
vibrios [1].
The CT that is made is comprised of six protein subunits: one A subunit and five copies of 
B subunits, generally denoted as AB5. B subunit is also known as the binding factor which 
binds to the GM1 ganglioside receptor of the epithelial cells of the small intestine. Once 
bound with the target cells, it forms a toxin complex which is then endocytosed by the cell. 
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As soon as the process of endocytosis takes place, the enzymatic activation of A subunit 
occurs leading to increased adenylate cyclase activity, thereby increasing the concentra-
tion of cAMP to more than 120-folds. This in turns leads to increased permeability of the 
chloride channels subsequently mediating the efflux of more ATP-mediated chloride ions 
and secretion of mere H
2
O, Na+, K+ and HCO
3
− into the lumen of the intestine [4, 5, 7]. The 
increased absorption of water as well as electrolytes is responsible for the massive dehydra-
tion leading to the clinical symptoms of cholera. The brief mechanism of pathogenesis is 
depicted in Figure 1.
2.3. Differential diagnosis
In places where cholera disease is found epidemic or endemic, treatment should never be 
delayed due to pending laboratory investigations; laboratory confirmation is very essential 
for the prophylaxis as well as for treatment in epidemic-endemic areas.
As outlined above, definitive diagnosis is required for which the most crucial step is the isola-
tion of V. cholerae from the stool of the infected individuals. For an epidemic survey, a further 
characterization rather than the isolation of Vibrio may not be required. In other circumstances, 
isolates should be typed by specific serum agglutination for O139 and O1 serotypes [9].
2.4. Therapy
The key to therapy is adequate rehydration till the disease has come to its end course (usually 
1–6 days in the absence of antibiotics). Rehydration can be accomplished by oral rehydration 
with oral rehydration solution (ORS) as in other cases of diarrhea and dysentery. In severe 
Figure 1. Mechanism of pathogenesis of V. cholerae.
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cases, intravenous infusion of fluid will be necessary. Antibiotics help to reduce the severity 
of illness and the duration of excretion of the organism. In children, hypoglycemia is treated 
with 25 or 50% glucose administered intravenously [10].
2.5. Intravenous rehydration
For adults, intravenous rehydration is done as fast as possible; 2 liters is administered the first 
30 minutes. If the condition of the patient improves at this point, the rate of infusion can be 
lowered to 100 ml/kg of the body weight within the first 4 hours of therapy. Children should 
receive 30 ml of the intravenous fluid per kg of body weight during the first hour and an 
additional 40 ml/kg in the following 2 hours [10, 11]. Both adults and children should receive 
appropriate amount of ORS during the course of illness. The rate and frequency of intrave-
nous infusion can be varied depending on the electrolyte loss from the stool of the patient. 
The World Health Organization (WHO) recommends Ringer’s lactate as the best rehydra-
tion solution. Isotonic saline corrects only hypovolemia, so potassium and glucose should be 
administered along with it for proper recovery from dehydration [12, 13].
2.6. Oral rehydration
Patients with moderate illness and dehydration can receive fluid replacement orally to com-
pensate for the water and electrolyte depletion. In mild cases, the WHO recommends 50 ml 
of ORS/kg of body weight to be given in the initial 4 h. For moderate dehydration, the quan-
tity should be increased to double, i.e., 100 ml/kg [11, 14]. Stool output should be continu-
ously monitored depending on which the rehydration therapy is optimized. For children, 
who tend to have high fluid losses, it should be replaced 1:1 with ORS. The oral solution 
used must be the one recommended by the WHO [1]. This solution consists of appropriate 
amount of electrolytes to balance the fluid and electrolyte losses due to dehydration. In 
addition, it also contains optimum quantity of glucose to facilitate the absorption of sodium 
and water.
The formula for the current WHO oral rehydration solution is 2.6 grams table salt (NaCl), 2.9 
grams trisodium citrate dihydrate, 1.5 grams (0.053 oz) potassium chloride (KCl) and 13.5 
grams anhydrous glucose (C6H12O6) per liter of fluid [1, 6, 12].
A homemade oral rehydration solution can be prepared when readymade sachet is not avail-
able. The composition of the ORS solution consists approximately of six level teaspoons of 
sugar and 1/2 a teaspoon of table salt in 1 liter of water. The molar ratio of sugar to salt should 
be 1:1, and the solution should not be hyperosmolar [9, 12].
2.7. Antimicrobial therapy
Treatment with antibiotics should start only after the initial rehydration therapy and correc-
tion of acidosis. Antibiotics play a secondary role in the treatment of cholera by shortening the 
length of cholera diarrhea as well as the excretion of vibrios. Though most of the V. cholerae 
strains have so far not exhibited any drug resistance, O139 strains have an intrinsic resistance 
to trimethoprim-sulfamethoxazole [14, 15]. Tetracycline is the usual drug of choice [7]. Rather 
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than the possibility of staining of teeth, tetracycline has not shown any contraindications in 
adult and children. Besides tetracycline, the quinolone group of antibiotics (ciprofloxacin and 
norfloxacin) has shown excellent in vitro activity against Vibrio [10, 11]. The widespread use 
of tetracycline as a prophylactic control is not recommended nowadays due to the emerging 
resistance toward it in the epidemic areas [14].
3. Epidemiology
Cholera is an indication of the prevalence of unsanitary conditions especially with the grow-
ing populations in developing countries. It is a plight that about 3–5 million cases of cholera 
are reported each year with the advancements of health and medical professionals across the 
globe [16]. When 52 countries reported 236,896 cases in 2006 with a fatality rate of 2.7%, a total 
of 589,854 cases were reported in 2011 from 58 countries [7]. These numbers suggest cholera 
being a global disease threatening worldwide.
In developing countries, where the population is high, cholera is the main cause of epidemic 
diarrhea. Global pandemic outbreaks are also being reported from Asia, Africa and Latin 
America [17]. Africa, being a country with limited medical facilities, has shown a considerable 
decrease in cholera outbreaks in the recent years. When 117,570 cases were reported in 2012, 
only 56,329 cases were reported in 2013 [16]. This shows a remarkable sanitary improvement 
as well as prophylactic measures adopted by the country. During 2013, Mexico and other 
Central African countries reported an outbreak, while 2014 witnessed a cholera outbreak in 
South Sudan. In an outbreak in Cuba, a total of 185 cases were reported in 2012 [18]. The WHO 
reports an average of 132,121 cholera cases in 2016 from 38 countries which includes 2420 
fatality reports [13].
Considering the epidemiology of the different serotypes and biotypes of V. cholerae, serogroup 
O1 and O139 cause outbreaks. The biotype EL Tor and serotype Ogawa are the main causes 
of epidemic cholera in developing countries [18, 19]. Among V. cholerae serogroups, O1 is the 
main cause of recent outbreaks. O139 was first identified in a massive outbreak in Bangladesh 
in the year 1992, but as of now, it is only seen in some sporadic cases [20]. It has not been 
reported outside Asia. The causative strain and serotype of Vibrio responsible for the first 
four pandemic is unknown, whereas the causative agents of the fifth and the sixth  pandemics 
were identified as classical biotypes of O1 strains and El Tor biotype, respectively [16]. In 
2010, Haiti outbreak was reported which was imported by the United Nations Peacekeeping 
Forces from South Asia. The United Nations report says it has affected 788,000 people and 
claimed the lives of 9200 people [16]. These information lead us to the fact that in the progress 
of epidemics and pandemics, new clones of toxigenic Vibrio strains continue to emerge which 
is one of the major threat to the countries who are the victims of the life-threatening disease.
Vibrio being the native species of the aquatic environment cannot be eradicated permanently 
from the globe as in the case of small pox [13]. There is an increased risk of epidemic and pan-
demic cholera with changes in the environmental and climatic conditions. As a prophylactic 
measure, integrated prevention strategies and interdisciplinary actions are required.
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4. Immune response and vaccines
Over 75 years of research has been done on the development of an effective vaccine against 
cholera. Since Vibrio does not exhibit much of antigenic variation, the very realistic goal of 
a cholera vaccine is very much near and attainable. The advanced study of the intestinal 
immune system and the pathogenicity of cholera have brought the insight of vaccine very 
much near.
4.1. Infection-derived immunity
The immunity induced by cholera infection is strain and serotype specific. Studies show that 
volunteers experimentally infected with classical biotype V. cholerae O1 showed 100% protec-
tion against subsequent infection against classical biotype vibrios [12]. Similarly, infection 
with El Tor biotype exhibited 90% immunity against El Tor vibrios [2]. The immunity lasts for 
a minimum of 3 years for the similar biotype. Initial infection with either the Ogawa or Inaba 
serotype conferred protection against both the serotypes during reinfection.
4.2. Components of the immune system
Infection with Vibrio can range from a fatal diarrheal disease to a mild non-clinical/unap-
parent case where only serological diagnosis is only possible [1, 12]. The reason for this 
remains unclear. But there have been certain assumptions regarding the symptomatic dif-
ference in the infected patients. One of them is the availability of the intestinal receptors for 
the toxins and the cholera vibrios in patients. After natural infection, circulating antibod-
ies are detected against most of the cholera antigens including flagellar (H) antigen, toxin 
and somatic (O) antigen [21, 22]. Antibodies raised against vibrios are referred to as “vib-
riocidal antibodies” since they lyse the bacteria in the presence of complement and other 
serum components. The parenteral administration of vaccines causes an apparent rise in 
the “vibriocidal antibodies” [2, 12]. The immune response consists of both antibacterial and 
antitoxic immunities, antibacterial immunity being the most predominant. An oral trial 
vaccine containing killed Vibrio conferred more resistance than parenteral vaccine consist-
ing toxoids. A  synergistic immune response consisting of both toxins and bacterial antigens 
showed remarkable immune response than single component [21].
It is likely that the primary immune response might be a main determinant of protection 
against cholera infection since it is essentially a disease of the small intestine. Moreover 
infants under breastfeeding are less likely to be affected due to the presence of the secretory 
antibodies present in the milk [19, 21]. Secretory IgA, IgM and IgG are found in the intestinal 
mucosa. These antibodies confer protective immunity in the presence and absence of com-
plementary proteins. The actual protection is due to the secretory IgA and other intestinal 
antibodies, and it is the vibriocidal antibodies in the serum which serves as the marker for 
IgA antibodies to direct against the same antigens [12, 21]. V. cholerae is a motile bacterium 
which is one of the major factors in the pathogenicity. The flagellar antibodies could prevent 
the invasion of the bacteria by immobilizing them; as well the somatic (O) and flagellar (H) 
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antibodies can cause clumping and lead to arrest of motion of cells. At the same time, the 
antitoxins can bind with the specific toxins at the epithelial surface and prevent the binding 
of the toxin [2, 12].
4.3. Vaccines
The observation that natural infection confers long-lasting immunity has led to the develop-
ment of cholera vaccines which can elicit protective immunity. The first attempts of vaccine 
development started in 1960, which focused on whole-cell vaccine preparation with paren-
teral administration. Ninety percent immunity was obtained, but it was not long-lasting as the 
antibody baseline titer waned in an year [21]. An attempt has also been made by converting 
cholera toxin to toxoid in the presence of glutaraldehyde and formalin, but it had elicited a 
very low level of protection as toxoid is a poor antigen [12].
In recent years, the importance of intestinal immune response has paved a different direc-
tion in vaccine development, i.e., a shift from parenteral to oral vaccines. Parenteral admin-
istration of antigens elicits the stimulation of secretory antibodies (IgA, IgG, and IgM), but 
the antibodies have a short life span and a poor memory [21]. In controversy to it, oral 
administration of antigens elicits immune response of a longer shelf life and good memory 
proving to be a good vaccine. There is not much contribution from serum antibody in chol-
era infection as V. cholera does not invade erythrocytes in the process of infection but only 
colonizes the intestinal mucosal surfaces. Therefore to stimulate the production of secretory 
antibodies, administration of oral vaccine plays a vital role when compared to parenteral 
vaccines [12, 21].
The FDA has approved a single-dose live oral vaccine for cholera called Vaxchora (lyophilized 
CVD 103-HgR) for the age group 18–64 years old [21]. Though it is not recommended in the 
usual immunization category, it is administered for travelers who are moving to a region 
actively spread with the toxigenic vibrios. As per the current scenario, there is no cholera vac-
cine which provides 100% protection, and vaccination is not recommended as a prophylactic 
measure in preventing cholera by the WHO.
The vaccines under trial consist of live attenuated whole-cell vaccines and killed bacterial 
suspensions, both of which are administered orally.
5. Laboratory investigations
5.1. Isolation and biochemical identification of the bacteria
Based on the somatic O antigens, currently there are about 130 serogroups of V. cholerae. 
However only O1 serogroup is involved in epidemic and pandemic cholera [12]. Isolation 
and identification of V. cholerae serogroup O1 or O139 from the stool sample of infected 
individuals is the gold standard in the diagnosis of the disease. The ideal transport 
medium is Cary Blair media; however, Alkaline Peptone Water (APW) medium is also 
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recommended (pH, 8.5) [1, 12]. The culture media are blood agar and MacConkey agar, 
the selective media being the thiosulfate-citrate-bile salts agar (TCBS). The rapid and pre-
sumptive diagnosis of cholera is the most important factor in the diagnosis, and hence the 
stool sample as soon as received is examined for a wet-mount preparation to look for the 
darting motility exhibited solely by Vibrio species [9, 12, 23]. Thus a presumptive identifica-
tion or probability of a cholera infection is made by which further treatment is carried out.
Overnight growth (18–24 hours) of V. cholerae on TCBS produces large (2–4 mm in diameter) 
yellow-colored colonies, slightly flattened with opaque centers and translucent peripher-
ies. The yellow color is due to the fermentation of sucrose in TCBS medium. Non-sucrose-
fermenting vibrios such as V. parahaemolyticus produce green to blue-green colonies. On 
MacConkey agar, the colonies are late lactose-fermenting colonies, initially being non-lactose 
fermenters [23]. Yellow colonies on TCBS agar are depicted in Figure 2.
Table 1 is taken from Laboratory Methods for the Diagnosis of V. cholerae, Centers for Disease 
Control and Prevention [12].
5.2. Serologic identification
As discussed previously, there are more than 130 serogroups of V. cholerae, among which O1 sero-
group is the causative agent of most of the epidemics and pandemics. Serologic  identification 
of V. cholera O1 serogroup is carried out by agglutination test with the specific antisera. This is 
the most rapid method and specific method of identifying V. cholerae O1 [16].
Isolates of O1 serogroup is further divided into three serotypes, namely, Ogawa, Inaba and 
Hikojima (rare). Strains that are positive with polyvalent O1 antisera are further tested for 
agglutination with Ogawa and Inaba antisera. In some instances, there may be strains that 
agglutinate very strongly and equally with both Ogawa and Inaba antisera. If ever such rare 
reactions are suspected, those strains should be referred to a reference laboratory for further 
confirmation and may be referred to as “possible serotype Hikojima” [9, 12].
Figure 2. Colony morphology of V. cholerae on TCBS—yellow color colonies.
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Table 2 is taken from Laboratory Methods for the Diagnosis of V. cholerae, Centers for Disease 
Control and Prevention [12].
5.3. Tests to distinguish biotypes of V. cholerae O1
The typing of V. cholerae O1 is not necessary for the identification and diagnostic point of view 
but is necessary for the epidemic surveillance in helping to identify the source of infection, 
particularly when cholera is prevalent in a particular geographical area [12]. There are two 
biotypes—classical and El Tor, among which El Tor biotype is predominant throughout the 
world and classical is rare except in certain regions of Bangladesh.
Table 3 is taken from Laboratory Methods for the Diagnosis of V. cholerae, Centers for Disease 
Control and Prevention [12].
5.4. Toxin assays
The virulence of the O1 serogroup is marked by the production of CT toxin. The CT molecule 
comprises one A (active) subunit and five B (binding) subunits. The B subunit attaches to 
Serotype Major O factors present Agglutination in absorbed sera
Ogawa Inaba
Ogawa A, B + −
Inaba A, C − +
Hikojima A, B, C + +
Table 2. Identifying characteristics of serotypes of V. cholerae serogroup.
Biochemical tests
Oxidase
String test
Kligler’s iron agar
Triple sugar iron agar
Glucose (acid production)
Glucose (gas production)
Sucrose (acid production)
Lysine
Arginine
Ornithine
Voges-Proskauer
Reaction
Positive
Positive
K/A, no gas, no H
2
S
A/A, no gas, no H
2
S
Positive
Negative
Positive
Positive
Negative
Positive
Variable*
*Most isolates of V. cholerae serotype O1 biotype El Tor are positive in the Voges-Proskauer test, whereas biotype classical 
strains are negative.
Table 1. Biochemical characteristics of isolates of V. cholerae O1.
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the GM1 ganglioside receptors on epithelial cells of the intestinal mucosa during the process 
of infection. After this process, cleavage occurs between the subunits so as to facilitate the 
entry of A component into the cell. The A1 component is responsible for the stimulation of 
adenylate cyclase which in turn produces cyclic AMP (cAMP) [3, 12]. Increased intracellular 
production of cAMP leads to disruption of electrolytes across the cell membrane leading to 
fluid secretion into the small intestine. When the fluid entering the intestine is greater than 
its reabsorption capability, it leads to diarrhea [12, 23]. CT toxin is similar to Escherichia coli 
(E. coli) heat labile toxin (LT) both antigenically and in mechanism. So, most of the toxin-
detecting assays are common for CT and LT. The mechanism of action of CT is well explained 
in “Mechanism of pathogenesis” and illustrated in Figure 2.
Before testing for the toxin, the isolate should be confirmed as V. cholera O1 strain. The non-O1 
serogroups also produce CT or other toxins similar to heat labile enterotoxin or Shiga toxin, 
but these toxins are not of diagnostic value as they have not yet been associated with epidemic 
disease [12].
5.4.1. Bioassays
5.4.1.1. Animal methods
The first cholera enterotoxin assay was the adult rabbit ileal loop method in the 1950s in 
which the enterotoxin was injected into the ligated segments of the intestine (ileal loops) of 
experimental animals such as rabbits, pigs, dogs and calves, and this caused accumulation 
of fluid. This mechanism is routinely used for the study of mechanism of CT, heat labile toxin 
of E. coli and other toxins. A cell-free supernatant is injected into each of the ileal loop after the 
exteriorization and ligation of the rabbit’s small intestine after which the abdomen is closed 
for 18 hours. The quantity of the accumulated fluid due to the stimulation of the toxin is 
measured by measuring the loops once the intestine is removed [12]. The disadvantage of this 
model is that it is time-consuming, cumbersome and difficult to standardize.
Another model was developed in 1955, the infant rabbit infection model which was also 
used for the determination of different toxins. Here, a 7-day-old infant rabbit is infected 
Property Reaction
Classical El Tor
Voges-Proskauer (modified with 1% NaCl) − +
Zone around polymyxin B (50 U) + −
Agglutination of chick erythrocytes − +
Lysis by bacteriophage
Classical IV
El Tor V
+
−
−
+
Hemolysis − +
Table 3. Differentiation of classical and El tor biotypes of V. cholerae serogroup O1.
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with the test culture either by gastric intubation or by intraluminal injection. A positive 
assay results in watery diarrhea of the rabbit and eventual death due to dehydration. The 
small intestine is removed, and the loops are measured to quantify the excess fluid accu-
mulation [8]. The drawback of this procedure is the requirement of one animal per test 
sample.
The vascular permeability factor assay is a dermal test wherein the activity of CT or LT is 
determined by the neutralization of standardized amount of specific antisera against CT. Here 
20–30 supernatants can be injected per rabbit. A cell-free supernatant is injected intradermally 
into the rabbit, following which Evans blue dye is injected intravenously. The increased cap-
illary permeability mediated by CT leads to perfusion of the dye in the skin causing a blue 
coloration with localized induration at the site of injection. The diameter of discoloration and 
induration is measured with a negative control [1, 12].
5.4.1.2. Tissue culture methods
Tissue culture methods are widely used in laboratories nowadays for the toxin assay. It 
requires skilled professionals and equipment in the laboratory with existing tissue culture 
facilities. It is a very sensitive assay with high reproducibility. In addition to detecting toxins, 
these assays are also useful in detecting toxin-neutralizing antibodies.
The Chinese hamster ovary (CHO) and the Y1 mouse adrenal (Y1) cell lines are used for the 
assay of CT and LT, although Vero monkey kidney cells are also used. The toxin if present in 
the cell-free supernatant increases the intracellular production of cAMP in the cell lines. This 
can be made out by the morphological changes in the cell lines (Y1 cells round and CHO cells 
elongate) [7, 12].
5.4.2. Immunoassays
5.4.2.1. Elisa
As CT and LT are immunogenic to both humans and animals, many immunogenic assays 
have been developed to detect the presence of toxins in vitro. As discussed earlier, the GM1 
ganglioside is the natural receptor for CT. In ELISA method, this GM1 ganglioside receptor 
is purified and is used for the preparation of ganglioside-capture enzyme-linked immuno-
sorbent assay. The cell-free supernatant in which the toxicity is to be tested is added to the 
microtiter wells coated with GM1 ganglioside. CT antiserum is then added on the plate to 
detect the binding of the toxin with the bound receptor on the plate, followed by the addition 
of enzyme-conjugated antiglobulin antibody [12].
5.4.2.2. Latex agglutination
In this assay, highly purified specific anti-CT is bound to latex particles. A commercial version 
of kit is available in the market which allows easy detection of cholera toxins in the laboratory.
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5.4.3. DNA-based assays
5.4.3.1. Polymerase chain reaction (PCR)
PCR is a molecular approach based on specific DNA sequences. In PCR, DNA polymerase 
enzyme is used to amplify certain specific sequences of DNA (amplicons) which can be 
detected on an agarose gel or using specific DNA probes [23]. The toxigenicity of V. cholerae 
can be detected by using PCR and primers that specifically amplify only CT genes. The advan-
tage of PCR is that it does not require a pure culture or even viable strains. The toxigenicity 
of the organism can be detected from the infected stool samples, contaminated water or food 
samples, thus determining the presence of Vibrio even without culturing it. The PCR method 
also has the advantage of detecting CT toxins that is produced in very low levels by certain 
strains, by identifying ctx genes possessed by them [12, 23]. The technical problems associated 
with radioisotopic labels have been solved by non-radioactive DNA labels such as biotin and 
digoxigenin. Apart from the fact that DNA-based assays require skilled professionals and 
sophisticated laboratories, these methods provide reliable, specific and rapid results unlike 
the conventional methods.
Table 4 is taken from Laboratory Methods for the Diagnosis of Vibrio cholerae, Centers for 
Disease Control and Prevention [12].
Assay Sensitivity 
(per ml)
Type of 
assay
Specific target of assay Sample tested
Rabbit ileal loop 30 ng Bioassay Stimulation of fluid 
accumulation
Culture supernatant
Infant rabbit assay 250–500 ng Bioassay Stimulation of fluid 
accumulation
Broth culture/supernatant
Rabbit skin test 0.1–3.5 ng Bioassay Permeability factor Culture supernatant
Y1 mouse adrenal cells 10 pg Bioassay Accumulation of  
cAMP
Culture supernatant
Chinese hamster
ovary cells
10 pg Bioassay Accumulation of  
cAMP
Culture supernatant
GM1-ELISA 10 pg Immune B subunit Culture supernatant
Coagglutination 50 ng Immune B subunit Culture supernatant
Reverse passive latex 
agglutination
1–2 ng Immune B subunit Culture supernatant
DNA probe Detects Ctx 
gene
Genetic Ctx gene DNA (colony blot)
Table 4. Commonly used assays for the detection of cholera toxin.
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6. Conclusion
V. cholerae is one among the most successful emerging and reemerging pathogens that has 
both human and environmental components in its life cycle. The epidemic and pandemic 
occurrence of V. cholerae especially V. cholerae O139 has been a turning point in the history of 
the most dreaded diarrhoeal disease—cholera. The conventional methods of screening and 
identification of these Gram-negative, motile bacilli are not sufficient enough for the rapid 
diagnosis of cholera. Although molecular methods have evolved for the identification of most 
of the serotypes and biotypes of V. cholerae, the most important factor to control the epidemic 
and pandemic of the dreaded, fatal, life-threatening disease is to sanitize the food and water 
environment as the most important prophylactic measure. India, Bangladesh and Sri Lanka 
have been victims of cholera epidemics, and now it is affecting a multitude of countries. Being 
developing countries, the concerned governments along with medical professionals should 
come up with certain safety measures and evoke the necessity of sanitization and cleanliness 
of the food and water systems to all people. Along with the above-said preventive measures, 
researchers and medical professionals are on the verge of producing an effective vaccine 
which will enable to boost the immune system of the individuals. As mentioned in the chap-
ter, the antigenic variation and shift of the organism are the hindrances in producing an effec-
tive vaccine. If people are immunized broadly, herd immunity results, with a decrease in the 
extent of contamination in the environment.
6.1. Future perspectives of the chapter
The Centers for Disease Control and Prevention (CDC) is always one step ahead in investi-
gating any cholera outbreaks across the globe. They have trained professionals and sophis-
ticated laboratory protocols for identification of toxigenic vibrios and emergence of any new 
antigenically modified strain as the Haiti outbreak. The WHO in collaboration with the CDC 
also provides information to the public and the health officials regarding the necessity of 
proper sanitization and preventive control measures to overcome the dreaded disease. The 
antigenic variation of the V. cholerae strains is one of the major limitations and hindrances in 
developing a 100% protective vaccination against it. The successful accomplishment of an 
effective vaccine will pave the way for a cholera-free globe so that the developed and the 
developing countries will not be able to face any more epidemics like the Haiti’s and the 
West Bengal O139.
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